Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Manifestaciones neurológicas en pacientes con COVID-19 severo en un centro de tercer nivel de atención / Neurological manifestations in patients with severe COVID-19 in a tertiary care center
Resumen
Resumen
Introducción: la enfermedad por SARS-CoV-2 denominada COVID-19 originada en China adquirió dimensiones pandémicas. De acuerdo con el reporte situacional de la OMS al 15 de marzo de 2021, la tasa de letalidad global es del 2.2%; en México se han confirmado alrededor de 194 944 defunciones por COVID-19. Estudios en China identificaron que los pacientes con COVID-19 severo, al compararlos con aquellos que cursaron con COVID-19 no severo, presentaron manifestaciones neurológicas más graves.
Objetivo: determinar la frecuencia de síntomas y manifestaciones neurológicas en pacientes con COVID-19 severo en un centro de tercer nivel de atención.
Material y métodos: estudio transversal, observacional y analítico, llevado a cabo en el Hospital de Especialidades del Centro Médico Nacional Siglo XXI, en pacientes hospitalizados con COVID-19 severo.
Resultados: se analizaron 183 casos, de los cuales 130 eran hombres (71%). La mediana de edad fue de 55 años (RIC: 44-65). Los síntomas neurológicos fueron: cefalea, anosmia y disgeusia. Las manifestaciones neurológicas se presentaron en 27 pacientes, la más frecuente fue la enfermedad vascular cerebral tipo isquémica (EVC) en 12 pacientes (44%) en pacientes con mayor edad, 76.5 frente a 54 años (p = 0.000), y con antecedente de enfermedad cardiovascular.
Conclusiones: los síntomas neurológicos más frecuentes fueron cefalea, anosmia y disgeusia. La manifestación neurológica más frecuente fue la EVC isquémica que se presentó en pacientes con COVID-19 severo de mayor edad y con antecedente de enfermedad cardiovascular.
Abstract
Background: The SARS-CoV-2 disease, called COVID-19, emerged in China has acquired pandemic dimensions. According to the WHO situational report of March 15, 2021, the global fatality rate is 2.2%; in Mexico, around 194 944 deaths have been confirmed by COVID-19. Studies in China identified that patients with severe COVID-19, when compared with those who had non-severe COVID-19, presented more severe neurological manifestations.
Objective: To determine the frequency of neurological symptoms and manifestations in patients with severe COVID-19 in a tertiary care center.
Material and methods: A cross-sectional, observational and analytical study was carried out at the Hospital de Especialidades del Centro Médico Nacional Siglo XXI, in patients hospitalized with severe COVID-19.
Results: 183 cases were analyzed, of which 130 were men (71%). The median age was 55 years (IQR: 44-65). The neurological symptoms were: headache, anosmia and dysgeusia. Neurological manifestations occurred in 27 patients (16%), the most frequent was ischemic-type cerebrovascular disease (CVD) in 12 (44%), in patients older than 76.5 years vs. 54 years (p = 0.000), with history of cardiovascular disease.
Conclusions: The most frequent neurological symptoms were headache, anosmia and dysgeusia. The most frequent neurological manifestation was ischemic CVD that appeared in older patients with severe COVID-19 with a history of cardiovascular disease.
Palabras clave
Texto completo:
PDFReferencias
World Health Organization. COVID-19. Weekly Epidemio logical Update Data as received by WHO from national authorities, as of 21 February 2021. Disponible en: https:// www.who.int/publications/m/item/weekly-epidemiological -update---23-february-2021.
SSA/SPPS/DGE/DIE/InDRE/UIES/Informe técnico. COVID-19 /México. Francisco de P. Miranda N° 157, Col. Lomas de Plateros, Demarcación Territorial Álvaro Obregón, C.P. 01480. CDMX. Tel. 800 00 44800 / 55 53 37 18 45.
World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020 (No. WHO/2019- nCoV/clinical/2020.4). World Health Organization.
Organización Mundial de la Salud. (2020). Definiciones de casos de COVID-19 utilizadas en la OMS: actualizadas en el documento titulado vigilancia de salud pública en relación con la COVID-19, publicado el 16 de diciembre de 2020. Organización Mundial de la Salud. https://apps.who.int/iris/ handle/10665/338330. Licença: CC BY-NC-SA 3.0 IGO.
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. Disponible en: https://doi.org/10.1136/ bmj.m1966.
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020:m1091. Disponible en: https://doi.org/10.1136/bmj.m1091.
Wu Z, Mc Googan JM. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention: JAMA. 2020;323(13):1239-42.
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. Disponible en: http://dx.doi.org/10.1001/ jama.2020.4683.
CDC COVID-19 Response Team (2020). Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR. Morbidity and mortality weekly report, 69(12):343-346. Disponible en: https://doi.org/10.15585/mmwr.mm6912e2.
Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16– 25. Disponible en: https://doi.org/10.1016/j.jinf.2020.04.021.
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71(15):896–7. Disponible en: https://doi.org/10.1093/cid/ ciaa415.
Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Severe obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50. Obesity (Silver Spring). 2020;28(9):1595–9. Disponible en: https://doi. org/10.1002/oby.22913.
Romero-Martínez M, Shamah-Levy T, Vielma-Orozco E. Encuesta Nacional de Salud y Nutrición (Ensanut 2018): metodología y perspectivas [National Health and Nutrition Survey 2018-19: methodology and perspectives. Salud Pública de Mexico. 2019;61(6):917–923. Disponible en: https: //doi.org/10.21149/11095.
Ahmed MU, Hanif M, Ali MJ, Haider MA, Kherani D, Memon GM, et al. Neurological manifestations of COVID-19 (SARSCoV-2): A review. Front Neurol. 2020;11:518. Disponible en: https://doi.org/10.3389/fneur.2020.00518.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6): 683–90 doi: 10.1001/jamaneurol.2020.1127.
Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, metaanalysis, and meta-regression. J Stroke Cerebrovasc Dis. 2020;29(8):104949 https://doi.org/10.1016/j.jstrokecerebrova sdis.2020.104949.
Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry: The ALBACOVID registry. Neurology. 2020;95(8):e1060–70. doi: 10.1212/ WNL.0000000000009937.
Favas TT, Dev P, Chaurasia RN, Chakravarty K, Mishra R, Joshi D, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci. 2020;41(12):3437–70 doi: 10.1007/s10072-020-04801-y.
Mahammedi A, Saba L, Vagal A, Leali M, Rossi A, Gaskill M, et al. Imaging of neurologic disease in hospitalized patients with COVID-19: An Italian multicenter retrospective observational study. Radiology. 2020;297(2):E270–3. doi: 10.1148/radiol.2020201933.
Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767–83. doi: 10.1016/S1474-4422(20)30221-0.
Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–8. Disponible en: https://doi.org/10.
Uncini A, Vallat J-M, Jacobs BC. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry. 2020;91(10):1105–10. doi: 10.1136/jnnp-2020-324491.
Guijarro-Castro C, Rosón-González M, Abreu A, GarcíaArratibel A, Ochoa-Mulas M. Síndrome de Guillain-Barré tras infección por SARS-CoV-2. Comentarios tras la publicación de 16 nuevos casos. Neurologia. 2020;35(6):412–5 doi: 10.1016/j. nrl.2020.06.002.
Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, et al. COVID-19 in patients with myasthenia gravis. Muscle Nerve. 2020;62(2):254–8. Disponible en: https://doi.org/10.1002/mus.26918 Albarran-Sanchez A et al. COVID-19 y manifestaciones neurológicas.
Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendonça RH, Souza PVS, et al. Myasthenia gravis and COVID-19: Clinical characteristics and outcomes. Front Neurol. 2020;11:1053. doi: 10.3389/fneur.2020.01053.
Aboukaïs R, Devalckeneer A, Boussemart P, Vromant A, Bricout N, Verdin M-F, et al. Impact of COVID-19 pandemic on patients with intracranial aneurysm rupture. Clin Neurol Neurosurg. 2021;201(106425):106425. doi: 10.1016/j.clineuro. 2020.106425.
Muhammad S, Petridis A, Cornelius JF, Hänggi D. Letter to editor: Severe brain haemorrhage and concomitant COVID-19 Infection: A neurovascular complication of COVID-19. Brain Behav Immun. 2020;87:150–1. Disponible en: https://doi. org/10.1016/j.bbi.2020.05.015.
Mas Maresma L, Barrachina Esteve O, Navarro Vilasaró M, Moreno-Ariño M. Miastenia gravis asociada a la infección por SARS-CoV-2: una conjunción de factores [Myasthenia gravis associated with SARS-CoV-2 infection: a conjunction of several factors. Revista espanola de geriatria y gerontologia. 2020;55(6):360–361. Disponible en: https://doi.org/10.1016/j. regg.2020.08.004.
Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med. 2020;173(12):1027–8. doi: 10.7326/L20-0845.
Enlaces refback
- No hay ningún enlace refback.